Discovery of Novel Drug-Conjugate Molecule ZM484 with Dual p53-MDM2 and TOP1 Inhibition for the Treatment of Colorectal Cancer
Journal of Medicinal Chemistry · 25.09.2025 · 68 (18) · 18988-19001
DOI: 10.1021/acs.jmedchem.5c01003 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 04.09.2025. Verfasst von Chuanhao Wang und 11 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Second Military Medical University, Shanghai 200433, P. R. China. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins c-mdm2, Tumor Suppressor Protein p53, Colorectal Neoplasms, Topoisomerase I Inhibitors. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 26 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
The blocking interaction between p53 and its negative regulator MDM2 is an engaging therapeutic strategy for antitumor drug development, and there are several drug candidates of p53-MDM2 inhibitors in clinical trials. In the present study, novel drug conjugates of p53-MDM2 inhibitors and topoisomerase I (TOP1) inhibitors have been designed based on bioinformatics analysis results of ten tumor tissues. Among them, ZM484 showed potent antiproliferative activity against three cell lines HCT116, SJSA-1, and A549, with the strongest p53-MDM2 and TOP1 inhibitory activity. Additionally, the treatment of compound ZM484 significantly reduced the tumor growth of HCT116 in BALB/c nude mice mode. Furthermore, our data highlighted the superior stability and good pharmacokinetic properties of compound ZM484. Using LC-MS analysis, we identified that compound ZM484 is capable of effectively releasing camptothecin (CPT) and the potent p53-MDM2 inhibitor 8a upon coincubation with DTT. Therefore, compound ZM484 could be a potential drug-conjugate candidate for the treatment of colorectal cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- School of Pharmacy, Second Military Medical University, Shanghai 200433, P. R. China.
- School of Chemistry and Chemical Engineering, Nanjing University of Science and Technology, Nanjing 210094, P. R. China.
- School of Chemical and Environmental Engineering, Shanghai Institute of Technology, Shanghai 201418, P. R. China.
- Department of Radiation Oncology, Changhai Hospital Affiliated to Naval Medical University, Shanghai 200433, P. R. China.
- School of Chemistry and Chemical Engineering, Henan Normal University, Xinxiang 453007, P. R. China.
ORCID-Profile: Junwu Zhu, Chunlin Zhuang, Zhenyuan Miao
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Wang, C., Chen, B., Yang, H., Huang, C., Zhang, Y., Yan, J., Zhang, D., Huang, A., Wu, Y., Zhu, J., Zhuang, C., & Miao, Z. (2025). Discovery of Novel Drug-Conjugate Molecule ZM484 with Dual p53-MDM2 and TOP1 Inhibition for the Treatment of Colorectal Cancer. Journal of Medicinal Chemistry, 68(18), 18988-19001. https://doi.org/10.1021/acs.jmedchem.5c01003
Vancouver
Wang C, Chen B, Yang H, Huang C, Zhang Y, Yan J, et al. Discovery of Novel Drug-Conjugate Molecule ZM484 with Dual p53-MDM2 and TOP1 Inhibition for the Treatment of Colorectal Cancer. Journal of Medicinal Chemistry. 2025;68(18):18988-19001. doi:10.1021/acs.jmedchem.5c01003
BibTeX
@article{Wang2025,
author = {Wang, Chuanhao and Chen, Baobao and Yang, Hang and Huang, Chengyi and Zhang, Yanming and Yan, Jianyu and Zhang, Daozuan and Huang, Anhua and Wu, Yuelin and Zhu, Junwu and Zhuang, Chunlin and Miao, Zhenyuan},
title = {Discovery of Novel Drug-Conjugate Molecule ZM484 with Dual p53-MDM2 and TOP1 Inhibition for the Treatment of Colorectal Cancer},
journal = {Journal of Medicinal Chemistry},
year = {2025},
volume = {68},
number = {18},
pages = {18988--19001},
doi = {10.1021/acs.jmedchem.5c01003}
}
EUVIMED